New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational ...

ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once ...

So now, you know, we have competing standards of care in the frontline for AML, which is either high intensity induction or ...

International trial led in part by Roswell Park tests ziftomenib with venetoclax and azacitidine, showing high response rates ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

BUFFALO, NY- October 11, 2024 – A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Transplant or no transplant for TP53 mutated AML.” As highlighted in this ...

With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...

Preliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rate Updated preliminary ...

CEO Angelos Stergiou highlighted new real-world AML data showing that most elderly patients never reach stem cell transplant despite achieving remission. ・The CEO also noted that earlier Phase 2 GPS ...